HER2 Breast Cancer

In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.

Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.

Yara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.

The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.

In the second article of a 2-part series, Yara Abdou, MD, provided a deep dive into the evolving landscape of HER2-targeted therapy and its potential to revolutionize cancer treatment.

In the first article of a 2-part series, Yara Abdou, MD, discussed the most significant challenges and transformative advancements in the treatment of HER2-positive breast cancer.

Treatment with trastuzumab maintains its place as the backbone of therapy in the first-line setting for management of patients with HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naive HER2-positive breast cancer.

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor, and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.

After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki showed promising antitumor activity in patients with chemotherapy-naïve, HER2-low, hormone receptor-positive metastatic breast cancer.

The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.

The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.

Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer.

In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.

Hatem Soliman, MD, discusses future directions for the HER2-positive breast cancer treatment landscape.

Johanna Kaufmann, PhD, discusses promising preclinical findings on first-in-class oncolytic viral therapy in breast cancer treatment.

In an interview, Funda Meric-Bernstam, MD, discussed the phase 2 DESTINY-PanTumor02 trial and the data on fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing cancers.

Progression-free survival in the central nervous system appears to be longer with trastuzumab deruxtecan than with comparator treatment in patients with HER2-positive metastatic breast cancer and brain metastases.

Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.